Alon Ben-Noon bought NRSN once, on Jun 16, 2026

Alon Ben-Noon is a biotech entrepreneur and the Co-Founder and Chief Executive Officer of NeuroSense Therapeutics Ltd. (Nasdaq: NRSN), a clinical- and late-stage biotechnology company focused on developing targeted combination therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease.( He founded NeuroSense in 2017 after being inspired by a meeting with ALS patient advocate Shay Rishoni, subsequently assembling a team of leading scientists and biotech professionals to advance multi-mechanism drug candidates such as the company’s lead ALS therapy, PrimeC.( As CEO, he leads NeuroSense’s strategy, clinical development programs, and investor-facing activities, frequently representing the company at industry conferences and public forums.(

Before establishing NeuroSense, Ben-Noon founded MediCan Consulting, a drug development consultancy serving a range of biotechnology clients, including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx, and NeuroDerm, where he specialized in designing and executing efficient, accurate, and innovative development programs.( He holds both an MBA and a BSc in Industrial Engineering from Ben-Gurion University, providing a combined technical and business foundation for his leadership in the neurodegenerative therapeutics space.(

Written by Perplexity from public sources.